These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 271142)

  • 41. Prognostic significance of serum lysozyme in adult acute myelogenous leukaemia.
    Currie G
    Lancet; 1976 Apr; 1(7964):835-7. PubMed ID: 56652
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Human acute myelogenous leukemia antigens defined by simian antisera: evidence for leukemia-associated antigens distinct from immune response-associated alloantigens.
    Mohanakumar T; Russell EC; Metzgar RS; Dunn N; Phibbs M; McWilliams NB; Maurer HM
    J Natl Cancer Inst; 1979 May; 62(5):1163-7. PubMed ID: 86633
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of continuous cell removal on blast cell kinetics in acute leukaemia.
    Hoelzer D; Kurrle E; Dietrich M; Meyer-Hamme KD; Fliedner TM
    Scand J Haematol; 1974; 12(4):311-20. PubMed ID: 4525533
    [No Abstract]   [Full Text] [Related]  

  • 44. Research on the clinical effect and in vitro study of HLA-mismatched hematopoietic stem cell infusion for acute myeloid leukemia.
    Zhang R; Zhao F; Wang J
    Hematology; 2015 Dec; 20(10):555-60. PubMed ID: 26067370
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of Compound Zhebei Granule () combined with chemotherapy on surface markers of leukemia stem cell in patients with acute myeloid leukemia.
    Wang J; Lai ZL; Chen XY; Li DY; Zhang YY; Ma W; Chu YT; Shi FQ; Yang L; Hou L
    Chin J Integr Med; 2016 Jun; 22(6):438-44. PubMed ID: 26666761
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessment of the mixed leucocyte reaction by target cell death: a study of leukaemic cells.
    Pegrum GD; Evans CA; Middleton VL; Balfour IC
    Clin Exp Immunol; 1972 Feb; 10(2):251-6. PubMed ID: 4505586
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lymphokine-activated killer cytotoxicity against leukaemic blast cells.
    Tratkiewicz JA; Szer J; Boyd RL
    Clin Exp Immunol; 1990 Apr; 80(1):94-9. PubMed ID: 2323104
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Generation of LAK cells in vitro in patients with acute leukemia.
    Parrado A; Rodriguez-Fernandez JM; Casares S; Noguerol P; Plaza E; Parody R; Espigado I; de Blas JM; Garcia-Solis D
    Leukemia; 1993 Sep; 7(9):1344-8. PubMed ID: 8371585
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cytotoxic antibody in normal human serums reactive with tumor cells from acute lymphocytic leukemia.
    Bias WB; Santos GW; Burke PJ; Mullins GM; Humphrey RL
    Science; 1972 Oct; 178(4058):304-6. PubMed ID: 4116712
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice.
    Lee EM; Yee D; Busfield SJ; McManus JF; Cummings N; Vairo G; Wei A; Ramshaw HS; Powell JA; Lopez AF; Lewis ID; McCall MN; Lock RB
    Haematologica; 2015 Jul; 100(7):914-26. PubMed ID: 26130514
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Surface Ia-like expression and MLR-stimulating capacity of human leukemic myeloblasts: implications for immunotherapy and prognosis.
    Miale TD; Stenke LA; Lindblom JB; Sjögren AM; Reizenstein PG; Udén AM; Lawson DL
    Acta Haematol; 1982; 68(1):3-13. PubMed ID: 6214917
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Active specific immunotherapy for acute myelogenous leukaemia.
    Powles R
    Johns Hopkins Med J Suppl; 1974; 3():333-40. PubMed ID: 4609353
    [No Abstract]   [Full Text] [Related]  

  • 53. Human acute myelogenous leukemia-associated antigens defined by a monkey antiserum to glycoproteins shed from leukemia myeloblasts.
    Mohanakumar T; Giedlin MA; Baker MA; Roncari DA; Taub RN
    Leuk Res; 1981; 5(1):11-7. PubMed ID: 6939949
    [No Abstract]   [Full Text] [Related]  

  • 54. Generation of autologous immunity to acute myeloid leukaemia and maintenance of complete remission following interferon-alpha treatment.
    Lowdell MW; Craston R; Prentice HG
    Cytokines Cell Mol Ther; 1999 Jun; 5(2):119-21. PubMed ID: 10515684
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Clinical studies and immunology in acute myeloid leukemia during chemo-immunotherapy].
    Lutz D
    Onkologie; 1981 Aug; 4(4):202-12. PubMed ID: 7029383
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy.
    Balleisen S; Kuendgen A; Hildebrandt B; Haas R; Germing U
    Leuk Res; 2009 Sep; 33(9):1189-93. PubMed ID: 19428106
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Thalidomide combined with interferon and interleukin-2 in treatment of relapsed or refractory acute myelogenous leukemia].
    Wei XD; Ai H; Mi RH; Chen L; Yuan FF; Hao QM; Yin QS; Wang P; Song YP
    Zhonghua Nei Ke Za Zhi; 2016 Nov; 55(11):875-877. PubMed ID: 27801345
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia.
    Paciucci PA; Cuttner J; Holland JF
    Semin Oncol; 1984 Sep; 11(3 Suppl 1):36-40. PubMed ID: 6385264
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chemotherapy of acute myelogenous leukaemia.
    Marie JP; Zittoun R
    Baillieres Clin Haematol; 1991 Jan; 4(1):97-113. PubMed ID: 2039863
    [No Abstract]   [Full Text] [Related]  

  • 60. Remission maintenance therapy in acute myelogenous leukemia.
    Embury SH; Elias L; Heller PH; Hood CE; Greenberg PL; Schrier SL
    West J Med; 1977 Apr; 126(4):267-72. PubMed ID: 266313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.